BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 37936202)

  • 1. Integrative multi-omics analysis unveils stemness-associated molecular subtypes in prostate cancer and pan-cancer: prognostic and therapeutic significance.
    Zheng K; Hai Y; Xi Y; Zhang Y; Liu Z; Chen W; Hu X; Zou X; Hao J
    J Transl Med; 2023 Nov; 21(1):789. PubMed ID: 37936202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
    Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
    J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer.
    Xie X; Dou CX; Luo MR; Zhang K; Liu Y; Zhou JW; Huang ZP; Xue KY; Liang HY; Ouyang AR; Ma SX; Yang JK; Zhou QZ; Guo WB; Liu CD; Zhao SC; Chen MK
    Front Immunol; 2022; 13():946209. PubMed ID: 36569837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
    Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
    J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients.
    Wang Z; Wang Y; Yang T; Xing H; Wang Y; Gao L; Guo X; Xing B; Wang Y; Ma W
    Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33839757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer.
    Zhang T; Li J; Dai J; Yuan F; Yuan G; Chen H; Zhu D; Mao X; Qin L; Liu N; Yang M
    Cancer Genet; 2023 Aug; 276-277():48-59. PubMed ID: 37487324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
    Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
    Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.
    JiaWei Z; ChunXia D; CunDong L; Yang L; JianKun Y; HaiFeng D; Cheng Y; ZhiPeng H; HongYi W; DeYing L; ZhiJian L; Xiao X; QiZhao Z; KangYi X; WenBing G; Ming X; JunHao Z; JiMing B; ShanChao Z; MingKun C
    Ann Med; 2021 Dec; 53(1):730-740. PubMed ID: 34032524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
    Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
    Cai D; Liu T; Fang J; Liu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
    Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
    J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer.
    Zhu W; Wu J; Huang J; Xiao D; Li F; Wu C; Li X; Zeng H; Zheng J; Lai W; Wen X
    Front Immunol; 2023; 14():1122670. PubMed ID: 37122696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-density lipoprotein receptor promotes crosstalk between cell stemness and tumor immune microenvironment in breast cancer: a large data-based multi-omics study.
    Yuan Q; Lu X; Guo H; Sun J; Yang M; Liu Q; Tong M
    J Transl Med; 2023 Nov; 21(1):871. PubMed ID: 38037058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of stemness features and construction of a stemness subtype classifier to predict survival and treatment responses in lung squamous cell carcinoma.
    Lai J; Lin X; Zheng H; Xie B; Fu D
    BMC Cancer; 2023 Jun; 23(1):525. PubMed ID: 37291533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer.
    Zhou R; Lu D; Mi J; Wang C; Lu W; Wang Z; Li X; Wei C; Zhang H; Ji J; Zhang Y; Zhang D; Wang F
    Sci Rep; 2024 Jun; 14(1):14107. PubMed ID: 38898043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options.
    Liu Z; Xu H; Weng S; Ren Y; Han X
    Front Immunol; 2022; 13():828330. PubMed ID: 35154148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients.
    Liu M; Zhou R; Zou W; Yang Z; Li Q; Chen Z; Jiang L; Zhang J
    Stem Cell Res Ther; 2023 Sep; 14(1):238. PubMed ID: 37674202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
    Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
    Liu W; Wang M; Wang M; Liu M
    Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.